Antibody drug conjugate are innovative biopharmaceutical products which are developed by linking a monoclonal antibody to a small molecule drug via a stable linker.
Global Cancer Antibody Drug Conjugate Market 2028 Report Highlights:
- Global Cancer Antibody Drug Conjugate Market USD 30 Billion Opportunity
- Global Market Sales Trends & Market Forecast Till 2028
- Market Analysis by County: US, Europe, Japan, China, South Korea, India, Australia, Taiwan, Canada
- Market by Indication: Breast Cancer, Lymphoma, Leukemia, Multiple Myeloma, Gastric Cancer, Lung Cancer
- Clinical Insight On 18 Approved Cancer Antibody Drug Conjugates
- Dosage, Price & Patent Insight On 18 Cancer Antibody Drug Conjugate
- Quarterly & Yearly Drug Sales Insight & Forecast Till 2028
- Clinical Insight On More Than 400 Cancer Drug Conjugates In Clinical Trials
- Competitive Landscape
Download Report:
https://www.kuickresearch.com/report-global-cancer-antibody-drug-conjugate-market
Antibody drug conjugate are innovative biopharmaceutical products which are developed by linking a monoclonal antibody to a small molecule drug via a stable linker. The breakthrough approval of first antibody drug conjugates in 2017 has gained momentum among pharmaceutical companies. To date, 18 antibody drug conjugates have been approved by regulatory bodies worldwide which are indicated for the management of cancers. The introduction of novel antibody drug conjugates have revolutionized the overall paradigm of cancer treatment by overcoming the limitations of conventional cancer therapies and following more targeted approach.
The introduction of antibody drug conjugate is acquiring attention from both large and small pharmaceutical companies. It has been observed that the potency of cytotoxic drug in the antibody-drug conjugate is 100-1000-fold more than the potency of the cytotoxic drug when it acts alone. Owing to their high efficiency, pharmaceutical companies have developed a robust clinical pipeline of drugs which are expected to enter the market during the forthcoming years. The major drugs in clinical development include mirvetuximab soravtansine, trastuzumab duocarmazine, camidanlumab tesirine, tusamitamab ravtansine, anetumab ravtansine, disitamab vedotin, and several others. Apart from monotherapy, scientists are also evaluating the role of antibody drug conjugates in combinational therapy, mainly with immune checkpoint inhibitors. Recently in January 2022, BioAtla entered into clinical collaboration with Bristol Myers Squibb to investigate BioAtla’s two lead CAB-ADC candidates, BA3011 and BA3021, in combination with Opdivo.
Further, the promising response of antibody drug conjugates as a therapeutic approach is moving forward, beyond its role in cancer. Several clinical trials are already underway to evaluate antibody drug conjugates for treatment of non-oncological indications, including autoimmune and cardiovascular diseases, diabetes, and antimicrobial infections. For instance, Seagen has initiated phase-II clinical trial to study the safety and efficacy of Adcetris in systemic sclerosis, an autoimmune disease of the connective tissue. These trends will boost the growth of market in forthcoming years.
As per report findings, the global antibody drug conjugate market is expected to surpass US$ 28 Billion by 2028. Several factors including rising geriatric population with increased risk of developing cancer, increasing emphasis on research and development, and large number of ongoing clinical trials are the major factors boosting the growth of market. Further, favorable government policies for life science companies and government funding are also expected to boost the antibody drug conjugates demand in near future. Also, strategic alliances can significantly accelerate a manufacture’s strategy to capitalize and capture a significant share in the global market.
Contact:
Neeraj Chawla
Research Head
Kuick Research
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com